Novavax Announced That Singapore's Health Sciences Authority Has Granted Full Approval For Its Prototype Covid-19 Vaccine Nuvaxovid For Active Immunization In Individuals Aged 12 And Older
Portfolio Pulse from Benzinga Newsdesk
Novavax has received full approval from Singapore's Health Sciences Authority for its Covid-19 vaccine, Nuvaxovid, for active immunization in individuals aged 12 and older.
October 18, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novavax's Covid-19 vaccine, Nuvaxovid, has been fully approved by Singapore's Health Sciences Authority for use in individuals aged 12 and older. This could potentially boost the company's revenues and stock price.
The full approval of Novavax's Covid-19 vaccine in Singapore could lead to increased sales and revenues for the company, which could positively impact its stock price. However, the extent of the impact will depend on the vaccine's market penetration and the company's ability to effectively distribute and market the vaccine.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100